Clinical

There is a synthetic lethality between sacituzumab govitecan and a PARP inhibitor, noted Aditya Bardia, MBBS, MPH, breast medical oncologist, Massachusetts General Hospital, Harvard Medical School.

Temporarily halting a trial to evaluate a vaccine means we are following the rules of safety, noted Maura Abbott, PhD, AOCNP, CPNP, RN, assistant professor of nursing at the Columbia University School of Nursing.

Combination treatments may be the future for treating patients with spinal muscular atrophy (SMA) at all stages and ages, explained Jill Jarecki, PhD, chief scientific officer at Cure SMA and research director of TREAT-NMD Neuromuscular Network.

New data on the long-term efficacy and safety of dupilumab are very reassuring to patients with asthma, explained J. Allen Meadows, MD, president of the American College of Allergy, Asthma & Immunology.

The Trump administration signed a $486 million agreement with AstraZeneca to develop a coronavirus disease 2019 (COVID-19) antibody treatment.

Patients with type 2-high asthma who were being treated with high-dose inhaled corticosteroids (ICS) had reduced exacerbations and improved lung function when they were switched to dupilumab.

Researchers identified 3 groups with distinctive patterns of overall survival (OS), among which they determined additional prognostic value in patients with <5% bone marrow blasts.

Older individuals need medications that focus on effects inside the nervous system, explained John Corboy, MD, of University of Colorado Denver, School of Medicine, and Rocky Mountain MS Center at Anschutz Medical Campus.

The research looked at inpatients with migraine on erenumab, and overall, found that the incidence was similar to patients in real-world settings.

Researchers found the nucleocapsid protein (NP) antigen of SARS-CoV-2, the virus which causes coronavirus disease 2019 (COVID-19), existed intracellularly in the ocular tissues of a patient who previously had COVID-19.

Newly diagnosed patients with multiple myeloma (MM) face a high risk of infection. A new study helps elucidate key risk factors.

Research on the long-term use of ozanimod in relapsing forms of multiple sclerosis (MS) has shown the treatment is effective with no new safety concerns.

Two women are awarded the Nobel Prize in Chemistry for CRISPR; Eli Lilly partners with DexCom, Inc; the US arm of AstraZeneca’s coronavirus disease 2019 (COVID-19) vaccine trial remains halted.

At a session Tuesday at the Migraine Trust International Symposium, one presentation delved into findings published this year in medication overuse headaches, prevention, and pathophysiology of migraine as well as cluster headaches.

In this study from Cape Town, South Africa, patients with comorbid HIV and a history of mental illness had an increased risk of mortality from all causes.

Targeted tumor delivery of irinotecan through sacituzumab govitecan can help to reduce treatment-related toxicities, noted Timothy A. Yap, MBBS, PhD, FRCP, medical director of the Institute for Applied Cancer Science, MD Anderson Cancer Center.

The National Insistutes of Health (NIH) study aims to discover new forms of diabetes, understand what makes them unique, and identify root causes.

Two Americans and a British scientist share the 2020 Prize for Physiology or Medicine for work in the 1970s through the 1990s. The rise of agents to treat hepatitis C virus has created vexing questions in managed care.

During a 1-hour free webinar from MJH Life Sciences™’s COVID-19 Coalition, experts discussed various myths around the coronavirus disease 2019 (COVID-19) pandemic.

Increasing at-home access to care and treatment options for spinal muscular atrophy (SMA) proved to be helpful during the coronavirus disease 2019 (COVID-19) pandemic, explained Mary Schroth, MD, FAAP, FCCP, chief medical officer at Cure SMA.

The study of over 8000 patients with myeloproliferative neoplasms (MPNs) also found that these patients were 40% more likely to have a prior diagnosis of inflammatory bowel disease (IBD).

A patient with chronic lymphocytic leukemia (CLL) was continued on ibrutinib even after developing severe coronavirus disease 2019 (COVID-19). He successfully overcame the infection.

Differences in long-term outcomes in patients with rheumatoid arthritis (RA) may because RA with and without autoantibodies are actually 2 distinct conditions.

Andre Goy, MD, of John Theurer Cancer Center, discussed what we’ve learned from existing chimeric antigen receptor T (CAR T)-cell therapies in managing cytokine responses.

Efficacy and safety of atezolizumab as first-line therapy for metastatic non–small cell lung cancer (NSCLC) with high levels of PD-L1 expression is not known, the authors said.

The majority of patients with asthma have type 2 inflammation, and the introduction of dupilumab has changed the treatment space for these patients, said Neal Jain, MD, FAAP, FAAAAI.

Study results presented during the virtual European Society for Medical Oncology meeting demonstrated the superiority of cemiplimab (Libtayo) plus ipilimumab vs cemiplimab monotherapy for non–small cell lung cancer.

A new review article said there are hurdles to bringing minimal residual disease (MRD) into the clinic as a decision-making tool, but the day is likely not far away.

Research into children and adolescents with nonremission acute lymphoblastic leukemia (ALL) has been sparse, but a new analysis suggests that allogeneic hematopoietic stem cell transplantation is a good fit for some patients.

The study is part of Moderna’s larger trial to find a vaccine to prevent coronavirus disease 2019, which puts older adults, who have weaker immune responses, at a higher risk of more severe illness and death.